Ludwig Enterprises Incの収益品質スコアはA-/60.436497です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
Ludwig Enterprises Incはいつ収益を報告しますか?
Ludwig Enterprises Incの次の収益報告はに予定されています
Ludwig Enterprises Incの予想収益はいくらですか?
ウォール街のアナリストによると、Ludwig Enterprises Incの予想収益は$です。
Ludwig Enterprises Incは収益予想を上回りましたか?
Ludwig Enterprises Incの最近の収益は$で、予想を。
主要データ
前終値
$0.019
始値
$0.016
当日レンジ
$0.0158 - $0.019
52週レンジ
$0.019 - $0.095
取引高
10.0K
平均取引高
14.8K
配当利回り
--
1株当たり利益(TTM)
-0.01
時価総額
$3.1M
LUDGとは何ですか?
Ludwig Enterprises Inc, operates as a biotech and healthcare holding company. The company is headquartered in Pompano Beach, Florida and currently employs 5 full-time employees. The company went IPO on 2007-12-11. Its proprietary mRNA genomic technology has the potential of screening for genetic biomarkers for inflammatory-driven diseases, including, but not limited to, heart disease, diabetes, preeclampsia, cancer and long COVID. The firm employs a non-invasive cheek swab test to collect mRNA samples. Its initial product candidate is the Revealia Breast test, a non-invasive cheek swab assay designed to detect molecular signatures in mRNA expression associated with the presence of breast cancer. Its technology platform integrates three key components: non-invasive sample collection, genomic analysis, and machine learning-based interpretation.